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tonin-norepinephrine retake inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs) 
are used for the short-term treatment of neuropathic pain. The cost-effectiveness of 
these three medications in Canada was examined. METHODS: A decision-tree ana-
lytic model compared the three drugs, over 18 weeks. Response rates were determined 
from two meta-analyses, “From-Placebo” and “Through-Placebo”. Outcomes of 
interest were rates of achieving 50% reduction in baseline pain (full-response) or 30% 
reduction (partial-response). A secondary outcome was the number of pain-controlled 
days (PCDs) applying full-response. The Ministry of Health (MOH) perspective
applied direct medical costs: medications, physician visits, diagnostic tests, and hos-
pitalizations; societal perspective (SOC) also applied indirect costs (productivity loss);
all in CN$2007. RESULTS: The “From-Placebo” approach yielded MOH (SOC) costs
of $380 ($1808); $448 ($2030); and $560 ($2063) for TCAs, SNRIs and ACs, respec-
tively, while primary outcomes were 79.3%; 76.4%; and 77.8%, and secondary
effective outcomes were 48 PCDs, 43 PCDs; and 46 PCDs for the same sequence. The
“Through-Placebo” approach yielded MOH (SOC) costs of $331 ($1513); $459
($1868); and $519 ($2125) for TCAs, SNRIs, and ACs, respectively, with primary 
(secondary) effectiveness outcomes of 88.0% (60 PCDs), 80.6% (41 PCDs); and 
84.3% (54 PCDs), for the same sequence. CONCLUSIONS: For both approaches,
TCAs provided the least costly alternative, and better outcomes, for both for primary 
and secondary effectiveness measures, effectively dominating SNRIs and ACs.
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OBJECTIVES: Development of a cost effectiveness analysis to evaluate treatment 
options for haemophilia patients with inhibitors in Germany. METHODS: Costs and 
outcomes of four different treatment regimens were compared by using an Excel-based
Markov model with a three month cycle length. Comparators are low- and high dose
protocols vs. strict on-demand treatment and to a mixture of both protocols after 
conducting a risk assessment. Time horizon: 18 years. Success rates of the different 
ITI-protocols, rates of anamnestic response, bleeding event rates and success rates for 
the treatment of bleeds were obtained from the literature. Costs included the costs for 
factor concentrates and hospitalization. Costs for one average patient were reported 
from a third party payers’ perspective. Annually discounting rates were 3% for costs
and 5% for beneﬁ ts. RESULTS: One average patient treated on-demand costs
€1,558,962.54 and has 181.92 minor and 2.43 severe bleeds. The cost for the same 
patient treated with the high dose ITI-protocol is approximately double (€3,340,976.81), 
but the patient has 2/3 fewer bleeds. The incremental cost per additional avoided 
minor bleed compared to on-demand treatment is €14,816.77 for the high dose pro-
tocol, €9,716.50 for ITI after risk assessment and €8,938.84 for the low dose protocol. 
The incremental costs per avoided bleed is €12,810.19 more for ITI after risk assess-
ment than for the low dose ITI protocol. When comparing the high dose ITI protocol
vs. ITI after risk assessment, each avoided bleed costs an extra €313,417.11. CON-
CLUSIONS: The results of the model suggest that use of risk assessment is the most 
cost effective approach to ITI. Although data on rare diseases are scarce and hard to
compare, decision-analytic modelling is a valuable tool to weight the costs and con-
sequences of different treatment regimens for patients with severe haemophilia com-
plicated by inhibitors.
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OBJECTIVES: To determine whether a Behavioral Internet Treatment (BIT) program 
for weight management is a viable cost-effective option, compared to the usual
care in a diverse sample of overweight (average BMI  29 kg/m2) healthy adults (mean
age 34) of the United States Air Force (USAF). METHODS: A 2-group parallel-
randomized controlled trial (N  442) outcomes were considered for this economic 
evaluation. Participants were randomly assigned into two groups 1) Usual Care (UC,
N  215) and 2) Usual Care plus Behavioral Internet Therapy (BIT, N  227). Individu-
als were evaluated twice, at baseline and at 6 months. Only statistically signiﬁ cant
primary outcome measures (changes in body weight, percent body weight changes and 
waist circumferences) and a secondary outcome measure (Weight Efﬁ cacy Life Style 
Questionnaire/WEL) were included in incremental cost effectiveness analysis (ICEA)
model. Costs of the intervention were computed by using the perspective of an agency 
wanting to replicate the intervention. Intervention costs consisted of: recruiting and 
training of telephone counselors, orientation, baseline and follow up appointments, 
paperwork and measurement costs. One-way sensitivity analyses were performed to
measure the robustness of this ICEA model. RESULTS: The intervention produced a
total direct cost of $7,993.32 for BIT intervention with a cost of $35.21/BIT partici-
pants. Total staff time costs were $64.58/BIT participants. The overall cost for the 
entire BIT intervention was $22,653.92 or $99.80/BIT participants. Intervention cost 
was $52.52 for each additional kg of weight loss. Additionally, intervention costs were
$58.70 for each cm waist circumference loss. On the WEL subscales costs were $76.77 
for each additional point gained on the social pressure subscale; where increasing 
scores indicate increased conﬁ dence in managing social pressures to eat. CONCLU-
SIONS: Although different forms of weight management program exist, the Behavioral 
Internet Therapy program is found to be a cost-effective choice for weight manage-
ment. Internet Therapy program is costly initially, but may provide a cost-saving 
long-term impact.
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OBJECTIVES: A variety of anti-TNF agents have been approved for the treatment of 
multiple autoimmune disorders. The objective of the current study is to compare the 
cost-effectiveness of these biologics across each drug’s approved therapeutic indica-
tions. METHODS: A systematic literature review was conducted of journal articles 
published during the period of 1998 to 2008 to identify all relevant cost-effectiveness 
analyses investigating the following three multiple indication drugs: adalimumab, 
etanercept, and inﬂ iximab. Speciﬁ cally, for adalimumab cost-effectiveness results were
analyzed for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis (PsO), 
and Crohn’s disease (CD); for etanercept cost-effectiveness results were analyzed for
RA, AS, and PsO; and for inﬂ iximab cost-effectiveness results were analyzed for RA,
AS, PsO, psoriatic arthritis (PsA), CD, and ulcerative colitis (UC). For each of the 
three therapies, the incremental cost-effectiveness ratios (ICERs) among their various
indications were compared. All costs were converted to 2007 USD using the Consumer 
Price Index (CPI) and Purchasing Power Parities (PPP) for comparison. RESULTS: A 
total of 25 cost-effective evaluations were included for comparative analysis. While 
all studies found adalimumab, etanercept and inﬂ iximab to be cost-effective for at 
least one indication (using a threshold of $50,000 – $100,000/QALY gained), ICER
values across approved indications varied greatly; for example, for inﬂ iximab, ICER
values as high as $290,000 were reported the treatment of RA, $75,000 for the treat-
ment of AS, $46,000 for the treatment of PsA, and $60,000 for the treatment of CD.
Reported ICER values for each indication also varied among studies as a result of 
differences between comparators, analytic timeframes, and study perspectives. CON-
CLUSIONS: Based on published ICER values, the cost-effectiveness of multiple indica-
tion drugs varies across approved indications. From an economic standpoint, although 
various biologic agents have approval for several indications, these drugs do not neces-
sarily offer a cost-effective solution across all approved indications.
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OBJECTIVES: The aim of this study was to assess the incremental cost-effectiveness
of on-demand versus prophylactic haemophilia therapy in Iran from the third-party
payers’ perspective. METHODS: A retrospective chart review of 25 types A haemo-
philiacs that treated in 3 hemophilia treatment center was conducted for patients aged
0–9 years receiving one of two treatments: 1) prophylaxis with concentrate at clinic;
2) concentrate at clinic as on-demand. Fourteen boys receiving on-demand infusions
for bleeding events and 11 boys receiving infusions prophylaxis. Data were collected
from documents obtained from the hemophilia treatment centers during a period of 
approximately 6 months. RESULTS: The patients receiving prophylactic treatment 
had fewer bleeding events each month (mean, 0.26 vs. 2.74) but used more concentrate
(225.31 vs. 87.20 units / kg per month). Average cost per patient each month at pro-
phylaxis group was about 1.9 times higher than on-demand group. Compared with 
on-demand infusion, prophylaxis costs 3201656 Rials (US $ 356) per bleeding event 
prevented. CONCLUSIONS: Prophylactic care markedly reduces the number of bleed-
ing episodes, but at considerable cost.
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OBJECTIVES: Patients with ﬁ bromyalgia (FM), a major cause of morbidity, use health 
services extensively and have an estimated prevalence of 3.4% for women and 0.5%
for men. The aim of this study was to assess the cost-effectiveness of pregabalin in 
the treatment of FM from the health care payer’s perspective. METHODS: We devel-
oped a three-state Markov model to simulate health and economic outcomes during
a time horizon of one-year (12-week cycles). The model includes several stages related 
to functional disability (mild-pain, moderate-pain and severe-pain). Effectiveness was 
assumed as the percentage of patients with no or mild pain (pain score 4) at the end 
of the follow-up period using a Visual Analogue Scale(VAS). Transition probabilities 
were obtained from a systematic review involving national and international published 
trials. Comparators used in the assessment were amitriptyline (25–50 mg/day); prega-
balin (150–450 mg/day); ﬂ uoxetine (20–80 mg/day); duloxetine (60–120 mg/day); 
gabapentin(300–1200 mg/day); tramadol(150–1300 mg/day)  acetaminophen(325–
2600 mg/day) and ﬂ uoxetine(20–80 mg/day)  amitriptyline(10–50 mg/day). Resource 
